Sunshine Biopharma Files Draft Information Statement

Sunshine Biopharma's draft information statement outlines shareholder authorization for discounted share issuance exceeding 20% of outstanding common stock. The October 13, 2026, authorization covers Series D Warrant exercise-price adjustments and proportional underlying share adjustments following share combinations. Share-combination adjustments could lower the initial $0.66 exercise price to a minimum of $0.275, increasing shares issuable proportionately. Shareholders also authorized voluntary reductions in Series D Warrant exercise prices at the board's discretion. The warrants were issued in an offering that closed October 9, 2026, raising approximately $6 million in gross proceeds. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities a